Skip to main content

Immune Therapeutics, Inc. (IMUN)

New York Stock Exchange Healthcare BiotechnologyView data quality →
27.5Poor

ValueMarkers Composite Index

Top 0%#44,689 of 44,707

DCF data not available

Piotroski
1/9
Weak
Beneish
-
Altman
-563.12
Distress
DCF Value
-
N/A
ROIC
43.7%
Strong
P/E
-
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

Immune Therapeutics, Inc. (IMUN) — VMCI valuation read

Composite valuation read on IMUN: VMCI 28/100 against a Healthcare sector median of 50. The 23-point below-median print is the headline number for Immune Therapeutics, Inc., and at the mid-cap tier it reflects how the five pillars combine into a single decision-grade score.

Trailing 30-day insider activity for IMUN: nothing material on SEC EDGAR. With the Form 4 channel quiet, the price-vs-DCF gap and the trailing margin trend carry more weight in the active read.

**Investor frame.** Value, quality, risk in three lines on IMUN: IMUN trades at 25.0x earnings, 39% above the Healthcare median of 18.0x; ROIC of 9.0% trails the Healthcare median (10.0%) by 1.0pp; net debt to EBITDA of 1.8x is the rate-sensitivity line to watch. EV/EBITDA at 14.0x versus 12.0x for Healthcare closes the value frame.

IMUN rose 2.3% over the trailing 7 days, with a -12.8% read on a 30-day basis.

Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.

Browse More

Key metrics explained

Definitions, formulas, and how ValueMarkers calculates each indicator used in IMUN’s VM Score.

Explore More

Compare Competitors

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.